Lineage Cell Therapeutics, Inc. (LCTX) — SEC Financial Statements & Analysis

Lineage Cell Therapeutics, Inc. (LCTX) is a biological products, (no diagnostic substances) company, incorporated in CA. Lineage Cell Therapeutics, Inc. trades on NYSE as: LCTX. Lineage Cell Therapeutics, Inc. (LCTX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Lineage Cell Therapeutics, Inc. carries a market cap of $326.84M, a P/E ratio of -10.14x, a P/B ratio of 5.47x, a P/S ratio of 24.98x, an enterprise value of $289.54M, and an EV/EBITDA multiple of -11.09x. On profitability, it posts a gross margin of 97.15%, an operating margin of -205.23%, a net margin of -246.40%, a Return on Equity (ROE) of -59.60%, a Return on Assets (ROA) of -32.72%, and a Return on Invested Capital (ROIC) of -187.25%. Per share, it reports EPS of $-0.13, diluted EPS of $-0.12, free cash flow per share of $-0.10, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of 19.87% year-over-year, net income growth of -21.18% year-over-year, and EPS growth of -27.85% year-over-year. On the balance sheet, it maintains a current ratio of 6.61x, a quick ratio of 6.44x, working capital of $44.95M, a debt-to-equity ratio of 0.78x, a debt ratio of 0.44, an interest coverage ratio of -17.41x, free cash flow of $-24.39M (TTM), and net debt of $-37.31M. Figures sourced from SEC EDGAR.

Market Cap

$326.84M

P/E TTM

-10.14x

EPS TTM

$-0.13

P/B TTM

5.47x

ROE TTM

-59.60%

ROA TTM

-32.72%

Debt To Equity

0.78x

Free Cash Flow TTM

$-24.39M

Net Revenue TTM Growth 1Y

19.87%

Data as of 2026-06-30 · Source: SEC EDGAR